Title : Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Pub. Date : 2009

PMID : 19358618






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Mean ADAS-cog scores of patients with mild AD demonstrated significant improvement from baseline with galantamine 16 and 24 mg/day (p < 0.001 for both), whereas cognitive function did not change significantly for placebo recipients (p = 0.559). Galantamine alkylglycerone phosphate synthase Homo sapiens
2 A greater proportion of patients treated with galantamine 16 mg/day (76% and 52% for mild and moderate AD, respectively) or 24 mg/day (69% and 61%, respectively) demonstrated a treatment response (i.e. ADAS-cog was maintained or improved) relative to placebo (55% and 28%, respectively; p < 0.05). Galantamine alkylglycerone phosphate synthase Homo sapiens